Primary Immunodeficiency Diseases Market – Industry Analysis and forecast (2022 to 2029)


Primary Immunodeficiency Diseases Market is expected to reach US$ 3.85 Bn. at a CAGR of 6.5 % during the forecast period 2029.

Primary Immunodeficiency Diseases Market Drivers and Restrains

Primary immunodeficiencies are disorders in which part of the body's immune system is missing or does not function normally. To be considered a primary immunodeficiency (PID), the cause of the immune deficiency must not be secondary in nature (i.e., caused by other disease, drug treatment, or environmental exposure to toxins). Most primary immunodeficiencies are genetic disorders; the majority are diagnosed in children under the age of one, although milder forms may not be recognized until adulthood. Rising prevalence of diseases such as selective IgA deficiency, and IgG subclass deficiency worldwide is fueling the Global Primary Immunodeficiency Diseases Market .The side-effects such as renal failure and allergic reactions associated with the treatment could hamper the Global Primary Immunodeficiency Diseases Market during forecast period. High-cost of the therapies is considered to be major restraint for global market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Primary Immunodeficiency Diseases MarketTo know about the Research Methodology :- Request Free Sample Report

Primary Immunodeficiency Diseases Market key segmentation

Global Primary Immunodeficiency Diseases Market is segmented by Disease, Test and Treatment. Based on disease the market is divided in to Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders. Antibody Deficiency is further sub-divided into Agammaglobulinaemia (X-Linked and Autosomal Recessive), Common Variable Immune Deficiency, Selective IgA Deficiency IgG Subclass Deficiency and Others. Cellular Immunodeficiency is further categorized into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott - Aldrich syndrome, DiGeorge Syndrome and Others. And Innate Immune Disorders is further segmented in to Complement Deficiencies, Hyper IgE Syndrome and Others. Among these, Cellular Immunodeficiency segment is expected to have market share of XX% during the forecast period because of rising patient population with this disease. By treatment the market is divided into Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem cell and Gene Therapy and Others. Among these Antibiotic therapy is expected share global market with XX%. There is no therapy that completely cures this disease thus, the goal is to prevent infections and improve quality of life using novel medications.

Primary Immunodeficiency Diseases Market Regional Analysis

Based on region the Global Primary Immunodeficiency Diseases Market is segmented into Asia Pacific, North America, Europe, Latin America and Middle East Africa. North America holds the highest share of Global Primary Immunodeficiency Diseases Market during forecast period. Increasing prevalence of diseases such as selective IgA deficiency, IgG subclass deficiency, and common variable immune deficiency has been witnessed in North America. In Europe, the market is expected have significant share of global market thanks to the increasing awareness regarding PIDD and favorable government support. The presence of companies such as Baxter International Inc., CSL Behring LLC, and Blotest Pharmaceuticals Corporation also supports the market’s expansion in the region. Asia-pacific is expected to grow with moderate CAGR of xx% during forecast period. The increasing willingness among people to spend on novel therapeutics fuels the global market in Asia Pacific.

The objective of the report is to present comprehensive analysis of Global Primary Immunodeficiency Diseases Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Primary Immunodeficiency Diseases Market dynamics, structure by analyzing the market segments, and project the Global Primary Immunodeficiency Diseases Market size. Clear representation of competitive analysis of key players by Primary Immunodeficiency Diseases Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Primary Immunodeficiency Diseases Market make the report investor’s guide.

Primary Immunodeficiency Diseases Market Scope: Inquire before buying






Global Primary Immunodeficiency Diseases Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 2.32 Bn.




Forecast Period 2022 to 2029 CAGR:
6.5%
Market Size in 2029:
US $ 3.85 Bn.




 Segments Covered:
by Disease
• Antibody Deficiency
• Cellular Immunodeficiency
• Innate Immune Disorder




by Test
• Blood Test
• Prenatal Testing




by Treatment
• Immunoglobulin Replacement Therapy
• Antibiotic Therapy
• Stem cell and Gene Therapy
• Others






Primary Immunodeficiency Diseases Market, by region

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Primary Immunodeficiency Diseases Market Key players are:

• Baxter International, Inc.,
• Biotest AG,
• CSL Behring LLC,
• Bio Products Laboratory Ltd.,
• Kedrion S.p.A.,
• LFB S.A.,
• Octapharma AG
• Grifols S.A
• Abbott,
• ADMA Biologics,
• Astellas,
• AstraZeneca,
• Bayer,
• Biocon,
• Bristol-Myers Squibb,
• BDI Pharma,
• Bharat Serums and Vaccines,
• Eli Lilly,
• GlaxoSmithKline,
• Hualan Biological Engineering,
• Kedrion Biopharma,
• Lupin Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Primary Immunodeficiency Diseases Market?
Ans: North America region held the highest share in 2021.

2. What is the growth rate of Global Primary Immunodeficiency Diseases Market?
Ans: The Global Primary Immunodeficiency Diseases Market is growing at a CAGR of 6.5 % during forecasting period 2022-2029.

3. What is scope of the Global Primary Immunodeficiency Diseases market report?
Ans: Global Primary Immunodeficiency Diseases Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Primary Immunodeficiency Diseases market?
Ans: The important key players in the Global Primary Immunodeficiency Diseases Market are – Baxter International, Inc.,, Biotest AG,, CSL Behring LLC,, Bio Products Laboratory Ltd.,, Kedrion S.p.A.,, LFB S.A.,, Octapharma AG, Grifols S.A, Abbott,, ADMA Biologics,, Astellas,, AstraZeneca,, Bayer,, Biocon,, Bristol-Myers Squibb,, BDI Pharma,, Bharat Serums and Vaccines,, Eli Lilly,, GlaxoSmithKline,, Hualan Biological Engineering,, Kedrion Biopharma,, Lupin Pharmaceuticals, and

5. What is the study period of this market?
Ans: The Global Primary Immunodeficiency Diseases Market is studied from 2021 to 2029. 




Global Primary Immunodeficiency Diseases Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Primary Immunodeficiency Diseases Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Primary Immunodeficiency Diseases Market Analysis and Forecast
6.1. Global Primary Immunodeficiency Diseases Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Primary Immunodeficiency Diseases Market Analysis and Forecast, by Treatment
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment
7.4. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Treatment
7.5. Global Primary Immunodeficiency Diseases Market Analysis, by Treatment
7.6. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Treatment

8. Global Primary Immunodeficiency Diseases Market Analysis and Forecast, by Test
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Test
8.4. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Test
8.5. Global Primary Immunodeficiency Diseases Market Analysis, by Test
8.6. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Test

9. Global Primary Immunodeficiency Diseases Market Analysis and Forecast, by Disease
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease
9.4. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Disease
9.5. Global Primary Immunodeficiency Diseases Market Analysis, by Disease
9.6. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Disease

10. Global Primary Immunodeficiency Diseases Market Analysis, by Region
10.1. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Region
10.2. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Region
10.3. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Region

11. North America Primary Immunodeficiency Diseases Market Analysis
11.1. Key Findings
11.2. North America Primary Immunodeficiency Diseases Market Overview
11.3. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment
11.4. North America Primary Immunodeficiency Diseases Market Forecast, by Treatment
11.4.1. Immunoglobulin Replacement Therapy
11.4.2. Antibiotic Therapy
11.4.3. Stem cell and Gene Therapy
11.4.4. Others
11.5. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Test
11.6. North America Primary Immunodeficiency Diseases Market Forecast, by Test
11.6.1. Blood Test
11.6.2. Prenatal Testing
11.7. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease
11.8. North America Primary Immunodeficiency Diseases Market Forecast, by Disease
11.8.1. Antibody Deficiency
11.8.2. Cellular Immunodeficiency
11.8.3. Innate Immune Disorder
11.9. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Country
11.10. North America Primary Immunodeficiency Diseases Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Primary Immunodeficiency Diseases Market Analysis, by Country
11.12. U.S. Primary Immunodeficiency Diseases Market Forecast, by Treatment
11.12.1. Immunoglobulin Replacement Therapy
11.12.2. Antibiotic Therapy
11.12.3. Stem cell and Gene Therapy
11.12.4. Others
11.13. U.S. Primary Immunodeficiency Diseases Market Forecast, by Test
11.13.1. Blood Test
11.13.2. Prenatal Testing
11.14. U.S. Primary Immunodeficiency Diseases Market Forecast, by Disease
11.14.1. Antibody Deficiency
11.14.2. Cellular Immunodeficiency
11.14.3. Innate Immune Disorder
11.15. Canada Primary Immunodeficiency Diseases Market Forecast, by Treatment
11.15.1. Immunoglobulin Replacement Therapy
11.15.2. Antibiotic Therapy
11.15.3. Stem cell and Gene Therapy
11.15.4. Others
11.16. Steel Canada Primary Immunodeficiency Diseases Market Forecast, by Test
11.16.1. Blood Test
11.16.2. Prenatal Testing
11.17. Canada Primary Immunodeficiency Diseases Market Forecast, by Disease
11.17.1. Antibody Deficiency
11.17.2. Cellular Immunodeficiency
11.17.3. Innate Immune Disorder
11.18. North America Primary Immunodeficiency Diseases Market Attractiveness Analysis
11.18.1. By Treatment
11.18.2. By Test
11.18.3. By Disease
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Primary Immunodeficiency Diseases Market Analysis
12.1. Key Findings
12.2. Europe Primary Immunodeficiency Diseases Market Overview
12.3. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment
12.4. Europe Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.4.1. Immunoglobulin Replacement Therapy
12.4.2. Antibiotic Therapy
12.4.3. Stem cell and Gene Therapy
12.4.4. Others
12.5. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Test
12.6. Europe Primary Immunodeficiency Diseases Market Forecast, by Test
12.6.1. Blood Test
12.6.2. Prenatal Testing
12.7. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease
12.8. Europe Primary Immunodeficiency Diseases Market Forecast, by Disease
12.8.1. Antibody Deficiency
12.8.2. Cellular Immunodeficiency
12.8.3. Innate Immune Disorder
12.9. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Country
12.10. Europe Primary Immunodeficiency Diseases Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Primary Immunodeficiency Diseases Market Analysis, by Country
12.12. Germany Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.12.1. Immunoglobulin Replacement Therapy
12.12.2. Antibiotic Therapy
12.12.3. Stem cell and Gene Therapy
12.12.4. Others
12.13. Germany Primary Immunodeficiency Diseases Market Forecast, by Test
12.13.1. Blood Test
12.13.2. Prenatal Testing
12.14. Germany Primary Immunodeficiency Diseases Market Forecast, by Disease
12.14.1. Antibody Deficiency
12.14.2. Cellular Immunodeficiency
12.14.3. Innate Immune Disorder
12.15. U.K. Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.15.1. Immunoglobulin Replacement Therapy
12.15.2. Antibiotic Therapy
12.15.3. Stem cell and Gene Therapy
12.15.4. Others
12.16. U.K. Primary Immunodeficiency Diseases Market Forecast, by Test
12.16.1. Blood Test
12.16.2. Prenatal Testing
12.17. U.K. Primary Immunodeficiency Diseases Market Forecast, by Disease
12.17.1. Antibody Deficiency
12.17.2. Cellular Immunodeficiency
12.17.3. Innate Immune Disorder
12.18. France Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.18.1. Immunoglobulin Replacement Therapy
12.18.2. Antibiotic Therapy
12.18.3. Stem cell and Gene Therapy
12.18.4. Others
12.19. France Primary Immunodeficiency Diseases Market Forecast, by Test
12.19.1. Blood Test
12.19.2. Prenatal Testing
12.20. France Primary Immunodeficiency Diseases Market Forecast, by Disease
12.20.1. Antibody Deficiency
12.20.2. Cellular Immunodeficiency
12.20.3. Innate Immune Disorder
12.21. Italy Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.21.1. Immunoglobulin Replacement Therapy
12.21.2. Antibiotic Therapy
12.21.3. Stem cell and Gene Therapy
12.21.4. Others
12.22. Italy Primary Immunodeficiency Diseases Market Forecast, by Test
12.22.1. Blood Test
12.22.2. Prenatal Testing
12.23. Italy Primary Immunodeficiency Diseases Market Forecast, by Disease
12.23.1. Antibody Deficiency
12.23.2. Cellular Immunodeficiency
12.23.3. Innate Immune Disorder
12.24. Spain Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.24.1. Immunoglobulin Replacement Therapy
12.24.2. Antibiotic Therapy
12.24.3. Stem cell and Gene Therapy
12.24.4. Others
12.25. Spain Primary Immunodeficiency Diseases Market Forecast, by Test
12.25.1. Blood Test
12.25.2. Prenatal Testing
12.26. Spain Primary Immunodeficiency Diseases Market Forecast, by Disease
12.26.1. Antibody Deficiency
12.26.2. Cellular Immunodeficiency
12.26.3. Innate Immune Disorder
12.27. Rest of Europe Primary Immunodeficiency Diseases Market Forecast, by Treatment
12.27.1. Immunoglobulin Replacement Therapy
12.27.2. Antibiotic Therapy
12.27.3. Stem cell and Gene Therapy
12.27.4. Others
12.28. Rest of Europe Primary Immunodeficiency Diseases Market Forecast, by Test
12.28.1. Blood Test
12.28.2. Prenatal Testing
12.29. Rest Of Europe Primary Immunodeficiency Diseases Market Forecast, by Disease
12.29.1. Antibody Deficiency
12.29.2. Cellular Immunodeficiency
12.29.3. Innate Immune Disorder
12.30. Europe Primary Immunodeficiency Diseases Market Attractiveness Analysis
12.30.1. By Treatment
12.30.2. By Test
12.30.3. By Disease
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Primary Immunodeficiency Diseases Market Analysis
13.1. Key Findings
13.2. Asia Pacific Primary Immunodeficiency Diseases Market Overview
13.3. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment
13.4. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Treatment
13.4.1. Immunoglobulin Replacement Therapy
13.4.2. Antibiotic Therapy
13.4.3. Stem cell and Gene Therapy
13.4.4. Others
13.5. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Test
13.6. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Test
13.6.1. Blood Test
13.6.2. Prenatal Testing
13.7. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease
13.8. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Disease
13.8.1. Antibody Deficiency
13.8.2. Cellular Immunodeficiency
13.8.3. Innate Immune Disorder
13.9. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Country
13.10. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Primary Immunodeficiency Diseases Market Analysis, by Country
13.12. China Primary Immunodeficiency Diseases Market Forecast, by Treatment
13.12.1. Immunoglobulin Replacement Therapy
13.12.2. Antibiotic Therapy
13.12.3. Stem cell and Gene Therapy
13.12.4. Others
13.13. China Primary Immunodeficiency Diseases Market Forecast, by Test
13.13.1. Blood Test
13.13.2. Prenatal Testing
13.14. China Primary Immunodeficiency Diseases Market Forecast, by Disease
13.14.1. Antibody Deficiency
13.14.2. Cellular Immunodeficiency
13.14.3. Innate Immune Disorder
13.15. India Primary Immunodeficiency Diseases Market Forecast, by Treatment
13.15.1. Immunoglobulin Replacement Therapy
13.15.2. Antibiotic Therapy
13.15.3. Stem cell and Gene Therapy
13.15.4. Others
13.16. India Primary Immunodeficiency Diseases Market Forecast, by Test
13.16.1. Blood Test
13.16.2. Prenatal Testing
13.17. India Primary Immunodeficiency Diseases Market Forecast, by Disease
13.17.1. Antibody Deficiency
13.17.2. Cellular Immunodeficiency
13.17.3. Innate Immune Disorder
13.18. Japan Primary Immunodeficiency Diseases Market Forecast, by Treatment
13.18.1. Immunoglobulin Replacement Therapy
13.18.2. Antibiotic Therapy
13.18.3. Stem cell and Gene Therapy
13.18.4. Others
13.19. Japan Primary Immunodeficiency Diseases Market Forecast, by Test
13.19.1. Blood Test
13.19.2. Prenatal Testing
13.20. Japan Primary Immunodeficiency Diseases Market Forecast, by Disease
13.20.1. Antibody Deficiency
13.20.2. Cellular Immunodeficiency
13.20.3. Innate Immune Disorder
13.21. ASEAN Primary Immunodeficiency Diseases Market Forecast, by Treatment
13.21.1. Immunoglobulin Replacement Therapy
13.21.2. Antibiotic Therapy
13.21.3. Stem cell and Gene Therapy
13.21.4. Others
13.22. ASEAN Primary Immunodeficiency Diseases Market Forecast, by Test
13.22.1. Blood Test
13.22.2. Prenatal Testing
13.23. ASEAN Primary Immunodeficiency Diseases Market Forecast, by Disease
13.23.1. Antibody Deficiency
13.23.2. Cellular Immunodeficiency
13.23.3. Innate Immune Disorder
13.24. Rest of Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Treatment
13.24.1. Immunoglobulin Replacement Therapy
13.24.2. Antibiotic Therapy
13.24.3. Stem cell and Gene Therapy
13.24.4. Others
13.25. Rest of Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Test
13.25.1. Blood Test
13.25.2. Prenatal Testing
13.26. Rest of Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Disease
13.26.1. Antibody Deficiency
13.26.2. Cellular Immunodeficiency
13.26.3. Innate Immune Disorder
13.27. Asia Pacific Primary Immunodeficiency Diseases Market Attractiveness Analysis
13.27.1. By Treatment
13.27.2. By Test
13.27.3. By Disease
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Primary Immunodeficiency Diseases Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Primary Immunodeficiency Diseases Market Overview
14.3. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment
14.4. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Treatment
14.4.1. Immunoglobulin Replacement Therapy
14.4.2. Antibiotic Therapy
14.4.3. Stem cell and Gene Therapy
14.4.4. Others
14.5. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Test
14.6. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Test
14.6.1. Blood Test
14.6.2. Prenatal Testing
14.7. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease
14.8. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Disease
14.8.1. Antibody Deficiency
14.8.2. Cellular Immunodeficiency
14.8.3. Innate Immune Disorder
14.9. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Country
14.10. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Primary Immunodeficiency Diseases Market Analysis, by Country
14.12. GCC Primary Immunodeficiency Diseases Market Forecast, by Treatment
14.12.1. Immunoglobulin Replacement Therapy
14.12.2. Antibiotic Therapy
14.12.3. Stem cell and Gene Therapy
14.12.4. Others
14.13. GCC Primary Immunodeficiency Diseases Market Forecast, by Test
14.13.1. Blood Test
14.13.2. Prenatal Testing
14.14. GCC Primary Immunodeficiency Diseases Market Forecast, by Disease
14.14.1. Antibody Deficiency
14.14.2. Cellular Immunodeficiency
14.14.3. Innate Immune Disorder
14.15. South Africa Primary Immunodeficiency Diseases Market Forecast, by Treatment
14.15.1. Immunoglobulin Replacement Therapy
14.15.2. Antibiotic Therapy
14.15.3. Stem cell and Gene Therapy
14.15.4. Others
14.16. South Africa Primary Immunodeficiency Diseases Market Forecast, by Test
14.16.1. Blood Test
14.16.2. Prenatal Testing
14.17. South Africa Primary Immunodeficiency Diseases Market Forecast, by Disease
14.17.1. Antibody Deficiency
14.17.2. Cellular Immunodeficiency
14.17.3. Innate Immune Disorder
14.18. Rest of Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Treatment
14.18.1. Immunoglobulin Replacement Therapy
14.18.2. Antibiotic Therapy
14.18.3. Stem cell and Gene Therapy
14.18.4. Others
14.19. Rest of Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Test
14.19.1. Blood Test
14.19.2. Prenatal Testing
14.20. Rest of Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Disease
14.20.1. Antibody Deficiency
14.20.2. Cellular Immunodeficiency
14.20.3. Innate Immune Disorder
14.21. Middle East & Africa Primary Immunodeficiency Diseases Market Attractiveness Analysis
14.21.1. By Treatment
14.21.2. By Test
14.21.3. By Disease
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Primary Immunodeficiency Diseases Market Analysis
15.1. Key Findings
15.2. South America Primary Immunodeficiency Diseases Market Overview
15.3. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment
15.4. South America Primary Immunodeficiency Diseases Market Forecast, by Treatment
15.4.1. Immunoglobulin Replacement Therapy
15.4.2. Antibiotic Therapy
15.4.3. Stem cell and Gene Therapy
15.4.4. Others
15.5. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Test
15.6. South America Primary Immunodeficiency Diseases Market Forecast, by Test
15.6.1. Blood Test
15.6.2. Prenatal Testing
15.7. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease
15.8. South America Primary Immunodeficiency Diseases Market Forecast, by Disease
15.8.1. Antibody Deficiency
15.8.2. Cellular Immunodeficiency
15.8.3. Innate Immune Disorder

15.9. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Country
15.10. South America Primary Immunodeficiency Diseases Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Primary Immunodeficiency Diseases Market Analysis, by Country
15.12. Brazil Primary Immunodeficiency Diseases Market Forecast, by Treatment
15.12.1. Immunoglobulin Replacement Therapy
15.12.2. Antibiotic Therapy
15.12.3. Stem cell and Gene Therapy
15.12.4. Others
15.13. Brazil Primary Immunodeficiency Diseases Market Forecast, by Test
15.13.1. Blood Test
15.13.2. Prenatal Testing
15.14. Brazil Primary Immunodeficiency Diseases Market Forecast, by Disease
15.14.1. Antibody Deficiency
15.14.2. Cellular Immunodeficiency
15.14.3. Innate Immune Disorder
15.15. Mexico Primary Immunodeficiency Diseases Market Forecast, by Treatment
15.15.1. Immunoglobulin Replacement Therapy
15.15.2. Antibiotic Therapy
15.15.3. Stem cell and Gene Therapy
15.15.4. Others
15.16. Mexico Primary Immunodeficiency Diseases Market Forecast, by Test
15.16.1. Blood Test
15.16.2. Prenatal Testing
15.17. Mexico Primary Immunodeficiency Diseases Market Forecast, by Disease
15.17.1. Antibody Deficiency
15.17.2. Cellular Immunodeficiency
15.17.3. Innate Immune Disorder
15.18. Rest of South America Primary Immunodeficiency Diseases Market Forecast, by Treatment
15.18.1. Immunoglobulin Replacement Therapy
15.18.2. Antibiotic Therapy
15.18.3. Stem cell and Gene Therapy
15.18.4. Others
15.19. Rest of South America Primary Immunodeficiency Diseases Market Forecast, by Test
15.19.1. Blood Test
15.19.2. Prenatal Testing
15.20. Rest of South America Primary Immunodeficiency Diseases Market Forecast, by Disease
15.20.1. Antibody Deficiency
15.20.2. Cellular Immunodeficiency
15.20.3. Innate Immune Disorder
15.21. South America Primary Immunodeficiency Diseases Market Attractiveness Analysis
15.21.1. By Treatment
15.21.2. By Test
15.21.3. By Disease
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Baxter International, Inc.,
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Biotest AG,
16.3.3. CSL Behring LLC,
16.3.4. Bio Products Laboratory Ltd.,
16.3.5. Kedrion S.p.A.,
16.3.6. LFB S.A.,
16.3.7. Octapharma AG
16.3.8. Grifols S.A
16.3.9. Abbott,
16.3.10. ADMA Biologics,
16.3.11. Astellas,
16.3.12. AstraZeneca,
16.3.13. Bayer,
16.3.14. Biocon,
16.3.15. Bristol-Myers Squibb,
16.3.16. BDI Pharma,
16.3.17. Bharat Serums and Vaccines,
16.3.18. Eli Lilly,
16.3.19. GlaxoSmithKline,
16.3.20. Hualan Biological Engineering,
16.3.21. Kedrion Biopharma,
16.3.22. Lupin Pharmaceuticals,

17. Primary Key Insights
  • INQUIRE BEFORE BUYING